The endocrine disrupting potential of monosodium glutamate (MSG) on secretion of the glucagon-like peptide-1 (GLP-1) gut hormone and GLP-1 receptor interaction. (4th January 2017)
- Record Type:
- Journal Article
- Title:
- The endocrine disrupting potential of monosodium glutamate (MSG) on secretion of the glucagon-like peptide-1 (GLP-1) gut hormone and GLP-1 receptor interaction. (4th January 2017)
- Main Title:
- The endocrine disrupting potential of monosodium glutamate (MSG) on secretion of the glucagon-like peptide-1 (GLP-1) gut hormone and GLP-1 receptor interaction
- Authors:
- Shannon, Maeve
Green, Brian
Willars, Gary
Wilson, Jodie
Matthews, Natalie
Lamb, Joanna
Gillespie, Anna
Connolly, Lisa - Abstract:
- Highlights: Monosodium glutamate (MSG) is a suspected obesogen. Endocrine disrupting effect of MSG on GLP-1 was assessed. Following 3 h exposure, MSG induced an increase in GLP-1 secretion. Following 72 h exposure, MSG caused a reduction in GLP-1 secretion. High content analysis assay highlighted pre-lethal cytotoxic effects of MSG. Abstract: Monosodium glutamate (MSG) is a suspected obesogen with epidemiological evidence positively correlating consumption to increased body mass index and higher prevalence of metabolic syndrome. ELISA and high content analysis (HCA) were employed to examine the disruptive effects of MSG on the secretion of enteroendocrine hormone glucagon-like peptide-1 (GLP-1) and GLP-1 receptor (GLP-1R), respectively. Following 3 h MSG exposure of the enteroendocrine pGIP/neo: STC-1 cell line model (500 μg/ml) significantly increased GLP-1 secretion (1.8 fold; P ≤ 0.001), however, 72 h exposure (500 μg/ml) caused a 1.8 fold decline (P ≤ 0.05). Also, 3 h MSG exposure (0.5–500 μg/ml) did not induce any cytotoxicity (including multiple pre-lethal markers) but 72 h exposure at 250–500 μg/ml, decreased cell number (11.8–26.7%; P ≤ 0.05), increased nuclear area (23.9–29.8%; P ≤ 0.001) and decreased mitochondrial membrane potential (13–21.6%; P ≤ 0.05). At 500 μg/ml, MSG increased mitochondrial mass by 16.3% (P ≤ 0.01). MSG did not agonise or antagonise internalisation of the GLP-1R expressed recombinantly in U2OS cells, following GLP-1 stimulation. InHighlights: Monosodium glutamate (MSG) is a suspected obesogen. Endocrine disrupting effect of MSG on GLP-1 was assessed. Following 3 h exposure, MSG induced an increase in GLP-1 secretion. Following 72 h exposure, MSG caused a reduction in GLP-1 secretion. High content analysis assay highlighted pre-lethal cytotoxic effects of MSG. Abstract: Monosodium glutamate (MSG) is a suspected obesogen with epidemiological evidence positively correlating consumption to increased body mass index and higher prevalence of metabolic syndrome. ELISA and high content analysis (HCA) were employed to examine the disruptive effects of MSG on the secretion of enteroendocrine hormone glucagon-like peptide-1 (GLP-1) and GLP-1 receptor (GLP-1R), respectively. Following 3 h MSG exposure of the enteroendocrine pGIP/neo: STC-1 cell line model (500 μg/ml) significantly increased GLP-1 secretion (1.8 fold; P ≤ 0.001), however, 72 h exposure (500 μg/ml) caused a 1.8 fold decline (P ≤ 0.05). Also, 3 h MSG exposure (0.5–500 μg/ml) did not induce any cytotoxicity (including multiple pre-lethal markers) but 72 h exposure at 250–500 μg/ml, decreased cell number (11.8–26.7%; P ≤ 0.05), increased nuclear area (23.9–29.8%; P ≤ 0.001) and decreased mitochondrial membrane potential (13–21.6%; P ≤ 0.05). At 500 μg/ml, MSG increased mitochondrial mass by 16.3% (P ≤ 0.01). MSG did not agonise or antagonise internalisation of the GLP-1R expressed recombinantly in U2OS cells, following GLP-1 stimulation. In conclusion, 72 h exposure of an enteroendocrine cell line at dietary levels of MSG, results in pre-lethal cytotoxicity and decline in GLP-1 secretion. These adverse events may play a role in the pathogenesis of obesity as outlined in the obesogen hypothesis by impairing GLP-1 secretion, related satiety responses and glucose-stimulated insulin release. … (more)
- Is Part Of:
- Toxicology letters. Volume 265(2017)
- Journal:
- Toxicology letters
- Issue:
- Volume 265(2017)
- Issue Display:
- Volume 265, Issue 2017 (2017)
- Year:
- 2017
- Volume:
- 265
- Issue:
- 2017
- Issue Sort Value:
- 2017-0265-2017-0000
- Page Start:
- 97
- Page End:
- 105
- Publication Date:
- 2017-01-04
- Subjects:
- Monosodium glutamate -- In vitro bioassays -- High content analysis -- GLP-1 -- Diabetes -- Obesity
Toxicology -- Periodicals
363.179 - Journal URLs:
- http://www.sciencedirect.com/science/journal/03784274 ↗
http://www.elsevier.com/journals ↗ - DOI:
- 10.1016/j.toxlet.2016.11.015 ↗
- Languages:
- English
- ISSNs:
- 0378-4274
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 8873.042000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 280.xml